SEC Form D filing

Akava Therapeutics Inc., 2026-02-19

An SEC Form D private-offering notice from Winnetka, IL, a $15,000,000 filer-stated offering target in Biotech. Filed 2026-02-19. The source filing is one click away. For companies that filed this week, open the live feed.

What this filing says

Akava Therapeutics Inc. site↗ Verified via SEC Form D

Biotech developing small molecule therapeutics that inhibit protein aggregation, enzymes and cancer pathways for neurodegenerative diseases like ALS and Alzheimer's disease; lead candidate AKV9 has FDA IND clearance for an ALS Phase I trial.

Filed 2026-02-19Filed to raise $15,000,000HQ (as filed) Winnetka, ILSector Biotech web-verified against the company’s own siteStage (inferred) EarlyCall status No reported sale
Source linked the Form D on EDGAR↗Website verified akavatx.com↗Named in the filing 5 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source